Clinical trials on hydroxychloroquine against the coronavirus will not resume in the Solidarity study of the World Health Organization (WHO), announced Wednesday the specialized agency of the UN, specifying that this decision was taken with participating countries.
After a controversy over a study published by the British review “The Lancet”, whose officials had subsequently withdrawn, the WHO announced two weeks ago that the tests, suspended, would resume.
But after analyzing several data and discussions with the executive group of Solidarity which brings together seven countries, it has been decided to “stop” these clinical trials, said the WHO in a statement.
“The data from Solidarity (including data from the Discovery clinical trial in France) and the recently announced results from the Recovery trial in the United Kingdom have both shown that hydroxychloroquine does not reduce the mortality of Covid-19 inpatients, compared to the standard of care,” said WHO.
The researchers will not recruit other patients to experiment with hydroxychloroquine in the Solidarity trial, the organization said.
This decision only applies to the conduct of the Solidarity trial and does not apply to the use or evaluation of hydroxychloroquine in prophylaxis before or after exposure to Covid-19.
During a virtual press conference in Geneva, Dr Ana Maria Henao Restrepo, from WHO, stressed that “on the basis of these analyzes and the study of the evidence produced (…), after deliberations, has been concluded that the hydroxychloroquine weapon will be withdrawn from the Solidarity Test”.
However, she stressed that the decision to stop trials of inpatients with Covid-19 did not concern the use or evaluation of this molecule as a preventive treatment for disease caused by the new coronavirus.